Background: A substantial number of patients who relapse and die from cutaneous melanoma (CM) are categorized as being at low risk by traditional staging factors. The 31-gene expression profile (31-GEP) test independently stratifies metastatic risk of patients with CM as low (Class 1, with 1A indicating lowest risk) or high (Class 2,with 2B indicating highest risk).
Cutaneous melanoma (CM) is the leading cause of death from skin cancer, with 91,270 diagnoses and 9320 deaths expected in 2018. 1 Assessment of an individual patient's risk of recurrence and death is based on the American Joint Committee on Cancer (AJCC) recommendations, which consider traditional staging factors such as Breslow thickness (BT) and ulceration. [2] [3] [4] Although the CM of the majority of patients is diagnosed with localized tumors and typically exhibits a favorable prognosis, recent studies have shown that patients with early-stage disease at diagnosis contribute a substantial number of deaths from melanoma. [5] [6] [7] [8] [9] National guidelines for the clinical management of patients with CM do not recommend intensive surveillance and adjuvant therapy for patients deemed at low risk by traditional staging criteria (stage I-IA). 10, 11 However, frequent clinical follow-up and imaging are recommended for patients deemed at high risk (stage IIB-IIIC), and this intensified surveillance protocol for patients with CM has been associated with early identification of recurrences. [12] [13] [14] [15] [16] [17] Additionally, contemporary therapeutic interventions, including targeted therapies and immunotherapies, have proved more efficacious when tumor burden is low. [18] [19] [20] [21] [22] Thus, as effective therapies move into the adjuvant setting, the identification of high-risk subsets of patients with early-stage CM becomes more important.
Previously published retrospective and prospective studies have demonstrated the validity and clinical utility of a 31-gene expression profile (31-GEP) test to assess tumor biology and accurately predict the metastasis risk of patients with CM (DecisionDx-Melanoma, Castle Biosciences, Inc, Friendswood, TX). 23 (Table I) , were entered onto the case report form by the staff at participating centers and on-site data monitoring was performed for all cases. Final data analysis was performed after completion of data collection with a censor date of October 2016. Patients included in the training set used for development of the test were not included in this analysis. The 31-GEP test was used to determine the molecular profile of each sample. Details of the classification algorithm have been reported previously. [23] [24] [25] The primary end points for this analysis were recurrence-free survival (RFS), which was defined as the time from diagnosis to local, regional, or distant recurrence, and distant metastasis-free survival (DMFS), which was defined as the time from diagnosis to identification of any distant metastasis. Melanoma-specific survival (MSS), which was defined as the time from diagnosis to a documented death from melanoma, was a secondary end point. 
RESULTS
We evaluated the 690 pooled cases from the prior studies that met the inclusion criteria for stage and duration of follow-up (Table I) . [23] [24] [25] We compared the MSS rates by stage for this pooled cohort with the rates for patients in the AJCC 8 th Edition database (Supplemental Table I ; available at http://www.jaad. org) and showed that for the patients in this study cohort, the rates are plus or minus 1% of those for patients in the AJCC 8 th Edition database, thus indicating that the survival rates for this cohort are similar. 4 Consistent with previously reported results, [23] [24] [25] 31-GEP Class 2 was an independent predictor of RFS, DMFS, and MSS, with the 5-year survival rates for all outcomes being significantly reduced for patients with a Class 2 result compared with those for patients with a Class 1 result (data not shown). As Class 2B results account for a significant proportion of the difference in risk, the expanded subclasses are reported for the remainder of this manuscript. Cases with 31-GEP Class 1A results had significantly higher RFS, DMFS, and MSS rates compared with those for cases with 31-GEP Class 2B (P \ .0001 for all comparisons [Fig 1, A-C] ). In multivariate analysis, molecular class and SLN positivity were independent predictors of RFS, DMFS, and MSS (Table II) (P \ .01 in all cases), whereas ulceration was significant for DMFS and thickness was significant for RFS and DMFS (Table  II) . Age, although not considered in the AJCC staging criteria, has been shown to be a predictor of MSS in melanoma. [27] [28] [29] When included in the multivariate analysis, age was not a statistically significant factor for this end point (Supplemental Table II ; available at http://www.jaad.org). However, a Class 2B 31-GEP result, positive node status, and thickness were independent predictors of MSS (P \ .05). On the basis of patient management workflows depending on population risks, 3 subpopulations of patients with CM with expected favorable outcomes 4 were selected for further analysis: those with negative SLN biopsy (SLNB) results, those with stage I to IIA disease, and those with thin tumors (BT, #1 mm [T1]).
SLN-negative patients
Of the 690 patients, 459 had an SLNB performed, with the results of 259 of them deemed SLN negative. To evaluate the ability of the 31-GEP to stratify SLNnegative patients into differential risk groups, Kaplan-Meier analysis was performed for the 31-GEP outcomes in SLN-negative patients (n = 259). SLN-negative/Class 2B patients had significantly worse RFS, DMFS, and MSS rates than did SLNnegative/Class 1A patients (P \.01 for both pairwise comparison and all comparisons [Fig 2] ). Class 1B/2A patients had similar RFS, DMFS, and MSS rates, which were decreased compared with those for Class 1A but significantly higher than those for Class 2B. In this subgroup, a Class 2 result identified 71.3%, 70.4%, and 78.6% of recurrences, metastases, and melanoma-specific mortality events.
Low-risk patients per guidelines (stage I to IIA)
For the 393 patients with stage I to IIA disease, Class 1A patients had significantly better 5-year RFS, DMFS, and MSS rates than did Class 2B patients (P \ .0001 for all comparisons [Fig 3, A-C] ). In the stage I to IIA group, 31-GEP Class 2B was the most significant predictor of RFS and DMFS in Cox multivariate analysis that included thickness, ulceration, and mitotic rate, whereas thickness was significant only for RFS (n = 216; Class 2B hazard ratio [HR], 7.33 for RFS and 4.26 for DMFS; P \ .05) recurrence-free survival SLN:
sentinel lymph node SLNB:
sentinel lymph node biopsy J AM ACAD DERMATOL VOLUME 80, NUMBER 1 (Table III) . Multivariate analysis for MSS was performed with use of binary 31-GEP class (Class 1 vs Class 2) because no patient with Class 1A experienced a melanoma-related death. Only 31-GEP Class 2 was a significant predictor of MSS (HR, 6.13; P \.05) in this group (Table IV) .
Patients with thin tumors
The majority of patients with thin tumors (T1) were low-risk Class 1 patients (251 of 281 [89.3%]), but importantly, 5.3% of patients with thin tumors (15 of 281) had a high-risk Class 2B result; 2.0% of T1a and 13.9% of T1b tumors were Class 2B. Patients with thin tumors demonstrated statistically significant differences in 5-year RFS rates, with Class 1A and Class 2B exhibiting rates of 96.8% and 64.6%, respectively (P \ .001 for all comparisons) ( Supplemental Fig 1, A; available at http://www. jaad.org). The DMFS rates for Class 1A and Class 2B were 97.2% and 84.4%, respectively (P = .007) ( Supplemental Fig 1, B ; available at http://www. jaad.org). Because there was only 1 confirmed melanoma-related death in this group, analysis of MSS was not possible. Cox multivariate analysis of There were 147 recurrences, 107 distant metastases, 36 melanoma-specific deaths. CI, Confidence interval; DMFS, distant melanoma-specific survival, 31-GEP, 31-gene expression profile; HR, hazard ratio; MSS, melanoma-free survival; RFS, recurrence-free survival. , and melanoma-specific survival (MSS) (C) rates for 690 patients were obtained by using molecular 31-GEP subclassification in Kaplan-Meier analysis. The tables below the curves show the number of patients with each 31-GEP class, 5-year survival rates for the outcome with 95% confidence intervals (CIs), and number of events with percentages of the class experiencing the event. P values were determined by the log-rank test.
Fig 2. Kaplan-Meier analysis of sentinel lymph nodeenegative (SLN neg) patients and 31-gene expression panel (31-GEP) class in the cohort of 690 patients with cutaneous melanoma (CM).
Recurrence-free survival (RFS) (A), distant metastasis-free survival (DMFS) (B), and melanomaspecific survival (MSS) (C) rates for patients with negative SLN biopsy results (n = 259) using molecular 31-GEP subclassification in Kaplan-Meier analysis. The tables below the curves show the number of patients with each 31-GEP class, 5-year survival rates for the outcome with 95% confidence intervals (CIs), and number of events with percentages of the class experiencing the event. P values determined by the log-rank test. J AM ACAD DERMATOL VOLUME 80, NUMBER 1 thickness, mitoses, ulceration, and SLNB positivity in patients with thin tumors who were node-assessed demonstrated that a 31-GEP Class 2B result was the only independent and significant predictor of RFS (n = 57; HR, 9.34; P = .004) (Supplemental Table III ; available at http://www.jaad.org).
DISCUSSION
National management guidelines for follow-up of patients with melanoma are based on AJCC stage, resulting in less intense surveillance recommendations for patients considered at low risk of recurrence. 10, 11 However, a majority of patients who eventually develop metastatic disease and die of melanoma are initially diagnosed as stage I or II, which indicates that there are tumors with a biologic propensity to metastasize that are currently not being identified. 7, 9, 30 Although SLNB remains an important prognostic tool in patients with melanoma, findings from the Multicenter Selective Lymphadenectomy Trial-1 study indicate that 2 of 3 patients who died of melanoma were SLN negative. 30 To address the unmet clinical need to identify those patients within traditionally low-risk patient subgroups who are at high risk of metastasis and death, we utilized a clinically validated 31-GEP test supported by prospective, retrospective, and clinical utility data [23] [24] [25] [26] [31] [32] [33] [34] [35] and 690 cases pooled from previous studies to permit subgroup analysis. Other prognostic molecular classifiers for CM have been reported; however, they are still in development and require additional validation 36, 37 or predict a clinical end point different for those described here. 38 Furthermore, none of these assays have demonstrated clinical utility in patient management.
Given the considerable number of deaths from stage I to IIA melanoma, adjuvant treatment may be relevant for high-risk, earlier-stage patients to prevent recurrences after definitive therapy. The 31-GEP test was able to identify a subset of stage I to IIA patients with a significant risk of recurrence and death; it was the strongest and only independent predictor of risk across all survival end points. Class 2B patients had an MSS rate comparable to that of patients with T3b tumors, whereas Class 1A patients had an MSS rate comparable to that of patients with T1a tumors. 4 Thin melanomas also comprise a substantial proportion of the melanomas of the overall patient population, and their incidence is steadily increasing. They also account for approximately 24% to 30% of deaths. 7, 8 Although a positive association of clinical features with poor outcomes for patients with thin tumors has been described, 39 the results show that the 31-GEP test is an additional independent predictor of recurrence, with a 5-year RFS rate of 64.6% for Class 2B patients compared with a rate of 96.8% for patients identified as Class 1A. As the 31-GEP test was developed and validated to determine 5-year risk of recurrence, the ability to detect the less well-characterized late recurrences (disease free interval of $10 years) with this prognostic test has yet to be elucidated. Seven percent of patients with thinner tumors in a single-institution study developed late recurrences. 40 Thus, with regard to predicting recurrences within 5 years of This study was limited by incomplete pathologic staging data owing to variation in contemporaneous reporting standards between 1998 and 2014 and lack of centralized pathology review. However, the study cohort reflects the current clinical situation wherein histopathologic assessment of CM may be prone to subjectivity, 44, 45 thus supporting a need for additional methods of risk assessment that are not subject to interobserver variability. As Cox regression analyses were performed by using only those cases in which all variables were identified, the number of cases included in each of the analyses, as indicated in each table, was less than the total number of cases. To address this limitation, Cox regression analysis was also performed including only the covariates of SLNB and 31-GEP subclass. Both SLN positivity and 31-GEP Class 2B remained independent predictors of recurrence in patients with T1 tumors (P # .005 for both [data not shown]). A second limitation is the retrospective nature of the sample collection. Another possible caveat is the proportion of stage III cases within the cohort. Although the overall cohort exhibited a higher rate of SLN positivity than that typically observed in clinical practice, the MSS outcomes for each stage aligned with the AJCC 8 th Edition staging outcomes (Supplemental Table I ), which indicates that from the standpoint of stage, the population is representative of contemporary patients with melanoma.
Our results confirm that the 31-GEP test is an independent prognostic factor, and the strongest prognostic indicator, compared to current staging factors. Managing these patients according to their individual risk (eg, by more frequent clinical followup and increased surveillance/imaging for early identification of metastatic disease) is consistent with current national guidelines. Furthermore, it is likely that there will be interest in evaluating contemporary adjuvant therapies in stage II patients. [46] [47] [48] To do this, identifying patient groups with high rates of metastatic events will be necessary for any clinical trial that includes this population. Supplemental Table I 
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